slow responder tirzepatide More than 1 in 4 adults with obesity had a novel physiologic subtype marked by fast gastric emptying, discordantly low postmeal GLP‑1 levels, and increased postmeal hunger. In a retrospective analysis, participants GLP-1 diabetes drugs like Muscle Health Size:(California Only)

slow responder tirzepatide More than 1 in 4 adults with obesity had a novel physiologic subtype marked by fast gastric emptying, discordantly low postmeal GLP‑1 levels, and increased postmeal hunger. In a retrospective analysis, participants GLP-1 diabetes drugs like Muscle Health Size:(California Only)

GLP-1 diabetes drugs like Ozempic may modestly reduce cancer risks | Reuters

Focus on the Game, Not the Plate: Engage in the action

Muscle Health

Size:(California Only)

The STEP-HFpEF trial randomised 529 patients with obesity (BMI ≥30 kg/m 2 ), HFpEF (left ventricular ejection fraction [LVEF] ≥45%) and New York Heart Association (NYHA) Class ≥II symptoms to once-weekly subcutaneous semaglutide 2.4 mg or placebo.9 The semaglutide group exhibited significant improvements in symptoms and physical limitations, assessed using the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), with the change in KCCQ-CSS being the primary trial endpoint.9 Semaglutide also resulted in significant improvements in secondary endpoints, including the 6-minute walk distance and weight loss